Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
US12384837B2 · kind B2 · utility
0Cited by
40References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2023 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Mar 13, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.